SPY772.04+0.09%QQQ745.40+0.12%BTC/USD84,948.99+0.61%DIA517.72+0.04%GLD393.05−0.09%TLT79.38+0.08%
Benzinga

Chemomab Therapeutics Ltd (CMMB) Stock Price, Quote, News & History

CMMBNASDAQ
Trade with Public
Trade with Public
$2.16
-0.04-1.82%
At close: Sep 25, 5:00 PM EST
$2.17
0.00980.45%
After Hours: Sep 25, 5:27 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareStock Report

Chemomab Therapeutics (CMMB) Stock Price, Quote, News & History | Benzinga

Key Statistics

Open
$2.20
Close
$2.16
Volume / Avg.
63.24K / 156.67K
Day Range
$2.10 - $2.26
52 Wk Range
1.35 - 3.58
Market Cap
$15.90M
P/E Ratio
-
Dividend Yield
-
Exchange
NASDAQ
RSI
40
Short Interest
1.15%
Days to Cover
1

Recent Chemomab Therapeutics Ltd News

Chemomab Therapeutics' Touts Positive Data From Experimental Drug For Chronic Liver Disease

Chemomab's OLE study of nebokitug in PSC patients confirmed safety and showed improvements in liver stiffness, fibrosis biomarkers, and cholestasis markers.
Vandana Singh

Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Avi Kapoor

Chemomab Therapeutics Reveals Data From Mid-Stage Study For Liver Disease Candidate, Stock Plunges On Capital Raise

Chemomab Therapeutics reports successful Phase 2 SPRING trial results for CM-101 in primary sclerosing cholangitis, showing safety and efficacy. Key findings include significant improvements in liver stiffness and pruritis, with a favorable safety profile.
Vandana Singh

What's Going On With Fibro-Inflammatory Disease Focused Chemomab Therapeutics On Tuesday?

Chemomab Therapeutics' CM-101 granted new patents in Brazil and Israel, currently in Phase 2 SPRING trial for primary sclerosing cholangitis. Topline data readout expected by mid-2024.
Vandana Singh

Why M.D.C. Holdings Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket

Shares of M.D.C. Holdings, Inc. (NYSE: MDC) rose sharply in today’s pre-market trading. Sekisui House, Ltd. and M.D.C. Holdings announced an agreement pursuant to which a wholly-owned subsidiary of Sekisui House will acquire MDC in an all-cash deal with an equity value of $4.9 billion.
Avi Kapoor

Financials

Quarterly
Annual
Name
Revenue
Change
Gross
Change
EBITDA
Change
EBIT
Change
Earnings
Change

Cash Flows

Operating Cash Flow (TTM)
-8.73M
Investing Cash Flow (TTM)
3.22M
Financing Cash Flow (TTM)
5.91M
Free Cash Flow (TTM)
-8.74M
Capital Expenditure (TTM)
-
Net Change in Cash (TTM)
403.00K

Analyst Rating and Forecast

12345
4.2
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Valuation Metrics

Enterprise Value
$5.46M
PE Ratio (TTM)
-
PE Ratio (FWD)
-
PEG Ratio (TTM)
-
PS Ratio (TTM)
-
PB Ratio (TTM)
1.86
Earnings Yield % (TTM)
-43.64%
Earnings Yield % (FWD)
-
EV / EBITDA (TTM)
-
Price / EBITDA (TTM)
-
Price / Free Cash Flow (TTM)
-
Book Value / Share
$1.19

Company Debt

Total Debt
-
LT Debt
-
LT Debt Issuance (TTM)
-
LT Debt Repayment (TTM)
-
Total Cash
$6.00M
Debt to Equity
-
Issuance of Debt (TTM)
-
Repayment of Debt (TTM)
-

Key Statistics

Open
$2.20
Close
$2.16
Volume / Avg.
63.24K / 156.67K
Day Range
$2.10 - $2.26
52 Wk Range
1.35 - 3.58
Market Cap
$15.90M
P/E Ratio
-
Dividend Yield
-
Exchange
NASDAQ
RSI
40
Short Interest
1.15%
Days to Cover
1

About

Sector
Health Care
Industry
Biotechnology
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that target...
Show More
Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

FAQ

Q

How do I buy Chemomab Therapeutics (CMMB) stock?

A

You can purchase shares of Chemomab Therapeutics (NASDAQ:CMMB) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Chemomab Therapeutics (CMMB) competitors?

Q

What is the forecast, or price target, for Chemomab Therapeutics (CMMB) stock?

A

Chemomab Therapeutics has a consensus price target of $27.00.

Q

What is the current price for Chemomab Therapeutics (CMMB)?

A

The stock price for Chemomab Therapeutics (NASDAQ: CMMB) is $2.1698 last updated September 25, 2026 at 5:27 PM EDT.

Q

Does Chemomab Therapeutics (CMMB) pay a dividend?

A

There are no upcoming dividends for Chemomab Therapeutics.

Q

When is Chemomab Therapeutics (NASDAQ:CMMB) reporting earnings?

A

Chemomab Therapeutics does not have any upcoming earnings scheduled.

Q

Is Chemomab Therapeutics (CMMB) going to split?

A

There is no upcoming split for Chemomab Therapeutics.

Q

What sector and industry does Chemomab Therapeutics (CMMB) operate in?

A

Chemomab Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved